OBJECTIVE: Assess immune and clinical changes with immunotherapy based on modified quantitative testing (MQT).
BACKGROUND: Immunotherapy promotes immunomodulation that occurs over several years. Quantitative testing offers the advantage of initiating immunotherapy with robust antigen concentrations. This study assessed whether changes in immune mediators and allergy symptoms occur rapidly using quantitative techniques.
METHODS: Sixteen allergic adults were tested using MQT. Subjects had serum drawn for immunoglobulins E and G4 (IgE, IgG4) to 3 antigens, Der p1, Der f1, and Fel d1, and for interleukins IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12, and IL-13, and IL-1 receptor antagonist (IL-1RA). Subjects also completed the Sino-Nasal Outcome Test-20 (SNOT-20), the Allergy Outcome Scale (AOS), and the Rhinosinusitis Disability Index (RSDI). They underwent MQT-based immunotherapy and completed outcome measures again at 6 and 12 weeks.
RESULTS: Nine subjects completed the study. Analysis demonstrated significant increases in IgG4 levels to all antigens, significant decreases in serum levels of IL-1β and IL-5, and significant increases in levels of IL-1RA. Improvement was also noted in AOS and RSDI subscales.
CONCLUSION: Immunotherapy based on MQT demonstrates significant changes in immunoglobulin and cytokine levels by 12 weeks following initiation. In addition, improvement in symptom and quality-of-life measures occurs by 12 weeks. These findings support the rapid onset of clinical effects with MQT-based treatment of inhalant allergy.
EBM rating: C-4
Get full access to this article
View all access options for this article.
References
1.
NoonLCantabBCProphylactic inoculation against hay fever. Lancet1911;10:1572–3.
2.
FornadleyJASkin testing in the diagnosis of inhalant allergy. In: KrouseJHChadwickSJGordonBR, et al editors. Allergy and immunology: An otolaryngic approach. Philadelphia: Lippincott, Williams and Wilkins; 2002;114–23.
3.
MabryRLSkin endpoint titration. New York: Thieme; 1992.
4.
HurstDSGordonBRFornadleyJA, et al. Safety of home-based and office-based allergy immunotherapy: a multicenter prospective study. Otolaryngol Head Neck Surg1999;121:553–61.
5.
KrouseJHMabryRLSkin testing for inhalant allergy 2003 Current strategies. Otolaryngol Head Neck Surg2003;129:S33–49.
6.
PeltierJRyanMWComparison of intradermal dilutional testing with the Multi-Test II applicator in testing for mold allergy. Otolaryngol Head Neck Surg2006;134:240–4.
7.
HaydonRCIIIGordonBRAeroallergen immunotherapy. In: KrouseJHChadwickSJGordonBR, et al editors. Allergy and immunology: An otolaryngic approach. Philadelphia: Lippincott, Williams and Wilkins; 2002;151–82.
8.
PengZNaclerioRMNormanPS, et al. Quantitative IgA and IgG subclass responses during and after long-term ragweed immunotherapy. J Allergy Clin Immunol1992;89:519–29.
9.
NandaAO'ConnorMAnandM, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol2004;114:1339–44.
10.
CreticosPSImmunotherapy. In: KaplanAP, et al editors. Allergy. 2nd ed.Philadelphia: WB Saunders; 1997;726–39.
11.
PastorelloEAIncorvaiaCZanussiC.Specific immunotherapy: clinical efficacy and mechanisms of action. Pharmacol Res1992; 26:46–7.
12.
OhashiYNakaiYTanakaA, et al. Allergen-specific immunotherapy for allergic rhinitis: a new insight into its clinical efficacy and mechanism. Acta Otolaryngol Suppl1998;538:178–90.
13.
GordonBRImmunotherapy: rationale and mechanisms. Otolaryngol Head Neck Surg1992;107:861–5.
14.
PiccirilloJFMerrittMGJrRichardsMLPsychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20). Otolaryngol Head Neck Surg2002;126:41–7.
15.
KemkerBJCoreyJPBrancaJ, et al. Development of the allergy outcome survey for allergic rhinitis. Otolaryngol Head Neck Surg1999;121:603–5.
16.
BenningerMSSeniorBAThe development of the Rhinosinusitis Disability Index. Arch Otolaryngol Head Neck Surg1997;123:1175–9.
